SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Apr 1, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: April 1, 2016 · CIK: 0001385818 · Accession: 0000000000-16-070686
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4720 April 1, 2016 Joshua R. Disbrow Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112
Re: Aytu Bioscience, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 15, 2016 File No. 000 -53121
Dear Mr. Disbrow:
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4720 April 1, 2016 Joshua R. Disbrow Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Re: Aytu Bioscience, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 15, 2016 File No. 000 -53121 Dear Mr. Disbrow: We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Alexander M. Donaldson, Esq. Wyrick Robbins Yates & Ponton LLP